Feeding behaviour and energy homeostasis are fundamental processes that are critical for survival. As such they represent important elements of the mechanism whereby fuel, stored in the form of adipose tissue is held constant. The adipostatic (or lipostatic) model, originally suggested by Kennedy in 1953, 1 hypothesizes that signals proportional to the size of fat stores are integrated into a complex regulatory system that includes signals generated by substrate depletion and replenishment, as well as biological rhythms, habits and learned associations. Key components of the adipostatic model are hormones whose circulating concentrations are proportional to adipose tissue mass, which act as tonic signals to the brain for regulating food intake and serve to maintain a constant body weight. A second set of signals, related to the quantity and quality of ingested food, consists of neural afferents and peptides released from the gastrointestinal tract in response to specific nutrients. The papers in this symposium cover recent work on both types of signals.
Leptin signalling to the brain
In his presentation entitled 'Leptin: physiologic role, signalling and resistance' Dr Jeffrey Flier reviewed our current knowledge of this newly identified hormone (unpublished review). The discovery of leptin has had a profound impact on our understanding of metabolic physiology. Leptin is a 16 kDa protein secreted by adipocytes and is thought to enter the brain to play a crucial role in the regulation of body fat levels and reproduction and in co-coordinating metabolism, feeding behaviour and energy balance. 2 In this proposed model increases of fat mass lead to elevations of plasma leptin that eventually induce a decrease in appetite and an increase in energy expenditure, whilst reductions in fat mass would have converse effects.
However, there are good reasons to question leptin's role as a circulating anti-obesity hormone since, in the vast majority of human obesity, plasma leptin concentrations are positively correlated with adiposity. Moreover, it is doubtful whether changes in circulating leptin levels at or above the physiological range control food intake or exert significant biological effect in the hypothalamus. Clinical trials with recombinant leptin demonstrate a lack of effect of peripheral leptin on body weight. 3 Similarly, in rhesus monkeys peripheral administration of leptin that produced increments in circulating leptin within the physiological range did not affect food intake. 4 However, administration of leptin intraventricularly caused a profound and dose-related inhibition of feeding. The lack of a biological effect at physiological levels has led to the concept of 'leptin resistance' (Figure 1 ), although there is no evidence in humans for a reduction in food intake in response to leptin. Conversely there is no acute change in blood leptin levels at meal times. 2 This suggests that circulating leptin is not a satiety signal, which raises the paradox of why leptin receptors are widely distributed in the brain, 5 where they are unlikely to be accessible to peripheral leptin.
We have suggested that leptin may actually be expressed in the brain, and we have now provided extensive evidence that the brain is a source of leptin, and that hypothalamic expression of the gene can be regulated by nutrients. 6 Much of this work is based on the demonstration of leptin gene expression in the hypothalamus, and in other brain areas, using reverse transcriptase polymerase chain reaction (RT-PCR). We have also confirmed the presence of leptin protein in these locations with immunohistochemistry using a variety of antibodies. We have studied the regulation of leptin expression in a brain-derived cell line, the rat C6 glioblastoma, and demonstrated differences from regulation in the adipocyte. 7 Our data on hypothalamic expression using RT-PCR confirms this and indicates that central expression of the gene may be regulated by nutrient, and by insulin (unpublished results; Morash B, Murphy P, Wilkinson M, Ur E. Effects of insulin on leptin gene expression in the brain and in a brain-derived tissue culture. CDA, Halifax, 2000).
Thus we would suggest that there are two regulatory systems served by leptin. The first, comprising circulating peptide derived from adipocytes, signals adequacy of the fat mass, via a blood-to-brain transport system. The second, derived from local hypothalamic expression, may regulate the well-characterized pathways mediated by cocaine and amphetamine-related transcript=pro-opiomelanocortin (CART=POMC) and by Agouti-related peptide=neuropeptide Y (AgRP=NPY).
Insulin signalling to the brain
In his article 'Insulin as an adiposity signal', Dr Stephen Woods reviews the role of insulin as a central signal and compares and contrasts this with leptin. 8 A role for insulin within the brain was first postulated by Woods and Porte in the 1970s, who suggested that the hormone worked centrally to cause a long-term, net catabolic response, decreasing food intake and increasing energy expenditure. 8 Supporting evidence for this view included the presence of insulin binding sites in brain areas linked to energy balance regulation, and the dose-dependent reduction of food intake seen with infusion of insulin directly into the CSF (important later studies by Woods have shown that this effect is not mediated by a noxious response or incapacitation). Since basal and stimulated levels of insulin correlate directly with body adiposity, insulin is well placed to fulfill the role of the long sought peripheral lipostatic factor. 8 Subsequent work by Woods and others has shown that, whilst there exists a dose response for the central anorectic effect of insulin, intracerebroventricular insulin is less effective when a higher proportion of dietary fat is consumed.
Conversely, reductions in central insulin activity, achieved through the administration of insulin antibodies into the ventral hypothalamus, or through neuron-specific disruption of the insulin receptor gene, results in hyperphagia and weight increase. Supporting evidence also comes from a natural mutant, the tubby mouse, which has a loss of function mutation that affects the intracellular insulin signalling pathway in cells of the ventral hypothalamus and is also hyperphagic and obese.
What role can central insulin signalling play in common forms of obesity? The central localization of insulin receptors, and insulin receptor substrate (IRS), correlates very well with the known distribution of leptin receptors 9 and leptin immunoreactivity. 6 These relationships are shown in Table 1 . This list illustrates the remarkable similarity in distribution of insulin-and leptin-sensitive sites in rat brain. The notable discrepancies (Â) in IRS-1-ir and Ob.R (ir vs mRNA) distribution require further study and may represent differences in techniques.
Is there evidence that co-localization of insulin and leptin is functionally significant? One important observation, made some time ago, is that obese fa=fa Zucker rats, with a mutation of the leptin receptor gene, do not reduce their food intake or body weight when given insulin i.v. 10 nor is NPY mRNA expression in the ARC altered 11 in comparison with lean controls. These findings suggest that central leptin activity is critical for insulin signalling, and are supported by more recent work. First, mice lacking IRS-2 gene expression are diabetic, resistant to insulin action, are hyperphagic and obese and exhibit hypothalamic resistance to leptin. 12 Second, brain-specific disruption of the insulin receptor gene using Cre-lox technology results in a phenotype with hyperphagia in female animals and obesity, hyperleptinemia and insulin resistance in both males and females. 13 These data reinforce the idea that CNS insulin resistance is Figure 1 The concept of leptin resistance. 
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associated with CNS resistance to leptin action. 14 Clearly an appreciation of the interdependence of these two signals will lead to a better understanding of how leptin and insulin contribute to obesity and type 2 diabetes mellitus.
Cytokines and feeding
Anorexia and cachexia, syndromes of depressed appetite, weight loss and wasting, complicate many diseases, including cancer, AIDS, chronic infection, and other critical illness. 15 Temporary anorexia during acute disease may be beneficial to an organism since a restriction in the intake of nutrients will inhibit tumour or bacterial growth. For example, force feeding during infection can increase morbidity and mortality. However, long-term anorexia during chronic disease is deleterious and may be associated with cachexia which can ultimately result in death. Both decreased caloric intake and an increased metabolic rate have been observed in cachectic patients, but little is known regarding the specific mechanisms responsible for altered appetite and metabolism under such cases. 16 Under normal circumstances, weight loss is a potent stimulus to food intake in humans and animals. The persistence of anorexia in cancer patients, therefore, implies a failure of this adaptive feeding response. 17 As anorexia and hypermetabolism play a role in the development of cachexia associated with cancer and sepsis, a number of groups have investigated the hypothesis that underlying abnormalities in the leptin feedback mechanism might be involved. For example, in rats bearing the Yoshida AH-130 ascites hepatoma, significant reductions in food intake occur by day 6 after tumour inoculation, although circulating leptin levels and adipocyte leptin mRNA expression are already low by day 4, before the animals show any anorectic behaviour. 18 Similarly in human subjects, in patients with tumours at different sites, serum levels of leptin are significantly lower than those of control subjects, but correlate with (reduced) body weight. 19 -21 An absence of plasma leptin would normally be associated with an increased appetite and decreased energy expenditure. Thus the observed anorexia suggests a disturbance in the hypothalamic part of the feedback mechanism.
Complex interactions among the nervous, endocrine, and immune systems converge in the hypothalamus and induce behavioural and metabolic responses which affect food intake and energy expenditure via neuropeptidergic effector molecules (eg corticotropin releasing hormone (CRH), CART, melanocyte stimulating hormone (MSH)). A number of proinflammatory cytokines, such as interleukin (IL) 1a, IL-6, tumour necrosis factor (TNF)a, ciliary neurotrophic factor (CNTF) and interferon (IFN)g, have been proposed as mediators of cancer cachexia. Serum levels of these cytokines have been shown to be significantly higher in subjects with cancer, as compared with healthy controls and inversely correlated with serum levels of leptin. 21 Thus, it has been suggested that cytokines may mimic the hypothalamic effect that is normally exerted by leptin. 17 This could occur by direct and persistent central stimulation of anorexigenic neuropeptides such as CRH, as well as by inhibition of the neuropeptide Y orexigenic network. However, there is considerable controversy surrounding this concept since the circulating concentrations required to recapitulate these effects are considerably higher than those found in physiological and pathophysiological states. This is likely related to the inability of cytokines to readily cross the blood -brain barrier (BBB). Cytokines of tumour-origin probably activate cells at the BBB to generate cellular signals within the brain, beyond the barrier cells. 22 Moreover, data obtained from tumour bearing rodents show that cytokine synthesis within the brain, and paracrine interactions represent a predominant mode of cytokine action. This model also proposes that through brain positive feedback systems, paracrine interactions can sustain local cytokine production independently of circulating cytokines. This model is consistent with the cascade pattern associated with cytokine production and with the ability of brain cells (eg microglia, astrocytes) to produce cytokines. Having shown that the brain is a source of the cytokine leptin, 6 we would suggest that tumour-derived cytokines such as IL-6 or CNTF may signal the hypothalamus to increase leptin gene expression. This would constitute the homeostatic equivalent of high peripheral leptin levels associated with a reduction in appetite.
Glucagon-like peptides
Glucagon-like peptide (GLP)-1 and GLP-2 are hormones derived from pre -pro-glucagon, which have diverse peripheral and central functions involving gastro-intestinal function and energy balance. GLP-1 and its cognate receptor are found in midline hypothalamic nuclei and in the brainstem in the caudal portion of the nucleus of the solitary tract (NTS). GLP-2 has a similar distribution, but expression of its receptor appears to be confined to the compact part of the dorsal medial hypothalamus (DMHc). Central administration of both peptides results in appetite suppression, a response consistent with their central distribution. However the precise role of the GLP system in the regulation of feeding behaviour and metabolism remains unclear.
To further elucidate the central role of GLP-1 and GLP-2 Tang-Christensen has studied the effects of intracerebroventricular administration of the peptides to food-deprived rats. 23 In this paradigm, increasing doses of GLP-1 result in a dose-dependent reduction in feeding behaviour, an effect that is reversed by the prior administration of the GLP-1 receptor antagonist (RA), exendin.
Central administration of GLP-1 also results in a reduction in angiotensin II-induced drinking, an effect which, again, is reversed by prior administration of the GLP-1 RA. In further studies Tang-Christensen has also shown that, in animals bearing neurochemical lesions of the arcuate nucleus (ARC; MSG treatment), the anorectic effect of GLP-1 is abolished.
However, the failure to suppress NPY induced feeding in these animals suggests that the target for GLP-1 is a pathway from the ARC to the PVN that is distinct from, but parallel to, the well-characterized NPY mediated connection between these nuclei. 23 Moreover, despite GLP-1's putative role as a centrally acting satiety factor, GLP-1 receptor knock-out mice have feeding behaviours, energy balance and body weight indistinguishable from wild-type animals. 24 This would suggest that, unlike leptin, GLP-1 is not essential for body-weight regulation, presumably because of compensatory satiety signals.
There is also evidence linking GLP-1 activity with leptin. For example, central administration of exendin prevents leptin induced anorexia and weight loss, 25 and leptin treatment has been shown to upregulate hypothalamic GLP-1. 26 On the other hand, there is also evidence suggesting that the two hormones operate within functionally distinct regulatory systems. For example GLP-1 receptor knockout in ob=ob mice does not lead to further effects on food intake or body weight, 27 and fos immunoreactivity in response to each of the peptides shows distinct patterns. It is fair to say that the complexities of these systems are far from understood.
In contrast to GLP-1, GLP-2 suppresses food but not water intake. The functional implications of the distinct GLP-2 system also remain unclear.
Gut feedback signalling
During a meal, a variety of signals are generated within the gastrointestinal tract that regulate further food intake. These include the release of local peptides as well as the activation of vagal afferent fibres. Mechanosensitive gastric vagal afferents fire in response to increasing gastric load volume, regardless of nutrient characteristics. Duodenal vagal afferents are activated by both load volume and nutrient character. Vagal afferent activity is also modulated by gastrointestinal peptides released in response to duodenal nutrients. For example, local arterial cholecystokinin (CCK) administration augments gastric vagal signals, apparently through a direct action. In contrast gastrinreleasing peptide (GRP) has indirect effects on vagal activity that are mediated by mechanical changes induced by the hormone.
There are a number of examples whereby disruption in GI feedback signalling results in significant behavioural alterations. Rats that have undergone vagal deafferentation consume larger less frequent meals. Otsuka Long Evans Tokushima Fatty (OLTEF) rats, are natural mutants that lack CCK A receptors (the subtype through which CCK activates vagal afferent fibres). These animals are obese, as a consequence of significant increases in meal size combined with an insufficient decrease in meal frequency.
The data highlighted by Moran reinforce the importance of gastrointestinal feedback signals in the control of meal size. 28 The papers presented at this symposium identify recent advances in our understanding of the endocrine and neuroendocrine signals that regulate energy balance. These excellent reviews confirm that our lack of knowledge in the field is exceeded only by our appreciation of the complexity of the mechanisms involved.
